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Dr Allan S. Stewart (New York, NY). Thanks for the privilege
of discussing this study. It really is a fantastic study with great
early results. Your team should be proud of having an under 1%
operative mortality for a complex operation.
It is a timely question, because right or wrong, we are changing
the paradigm for howwe are dealing with aortic valve disease. Sur-
geons are now implanting biological valves in younger and youn-
ger people, believing the propaganda from our device companies
that the new valves are going to last 20, 25 years, and by that point
in timewewill have worked out the valve-in-valve issue. So in that
30-year-old patient, we are suggesting that there might be just 1 bi-
ological replacement followed by 1 or 2 valve-in-valves. Essen-
tially, we are currently treating patients to prepare for
a technology that is so far unapproved.
So, with that in mind, I have a few questions. The first of which
is age. Your average age was low, around 40 years old, but you do
have 1 or 2 patients whowere older than 60. You are advocating for
valve-sparing operations with few data to support a 20-year
follow-up.
What do you tell your patients as far as the perceived longevity
of a trileaflet or a bicuspid valve?
Dr Kvitting. Thank you very much, Dr Stewart, for your very
insightful comments and questions. I should be careful to make
comments on behalf of Dr Miller in this forum. But, in general,
if the valve is repairable, it should be saved. If there are intraoper-
ative findings that the valve and cusps are not suitable for repair,
the valve should be excised, and the patient should receive a pros-
thetic valve. In older patients with a bicuspid aortic valve, because
they will eventually become stenotic sooner than in young pa-
tients, there are other options that could be better than valve-spar-
ing aortic root replacement; for example, a composite valve graft
with a bioprosthesis or a Freestyle root replacement, which prob-
ably would give the patients a more durable result.126 The Journal of Thoracic and Cardiovascular SurgDr Stewart. The second question I had is on bicuspid valves. It
is a struggle now when we think about bicuspid valves in the set-
ting of perhaps transcatheter valve rescue, because at the end of the
day, it is still a bicuspid valve. It still has the same altered geometry
of the annulus after a valve-sparing procedure; we are still plicat-
ing that conjoined leaflet and creating a more pronounced raphe.
So when that valve fails in the future, might we be doing a disser-
vice to our patients, because in its current iteration, our transcath-
eter solutions do not provide us a rescue for bicuspid valves,
whether it is a native bicuspid or a valve-sparing bicuspid repair.
Dr Kvitting. That is a very good comment. If the transcatheter
aortic valve replacement method holds its promise, it might be that
these patients are better off if they receive a composite graft with,
for example, a 3F equine valve or another bioprosthesis that later
will be more suitable for a valve-in-valve transcatheter aortic valve
replacement procedure. But I still think that it is uncertain whether
that leap of judgment will hold.
Dr Stewart. The next question is, when looking at your data,
you had 3 early failures, all of which had severe preoperative aortic
insufficiency (AI). You only treated 28 patients who started off
with severe AI, so that is a little greater than a 10% early failure
rate in those with severe AI. The 2 questions I have on that are,
1, in the practice of your group, have you altered how you repair
severe AI or perhaps abandoned doing severe AI? The third part
of it is, philosophically, in those young patients who have 4.7-,
4.8-cm aortas, 2 to 3+ AI, you know they are going to require an
operation at some point. Should we be advocating an earlier fix?
I bring this up because when you have severe AI for a while,
you are creating a lot of pressure down on the free edge of those
cusps and destroying it, and perhaps that is a risk factor for early
failure in a valve-sparing operation.
DrKvitting.Another good point. Three patients had severe aor-
tic regurgitation at the initial surgery and sustained structural valve
deterioration; 1 was a bicuspid valve with ruptured commissural
suspensory chords that was fixed by resuspending the cusp with
Gore-Tex suture neochords, which also was done in 2 other pa-
tients. Since that early failure, Dr Miller has abandoned this ap-
proach to correct ruptured suspensory chords with Gore-Tex
sutures. The 2 other patients were both very young and hadMarfan
syndrome; both developed dilatation of their left ventricular out-
flow tract as the mechanism responsible for their recurrent aortic
regurgitation. One of them, an 11-year-old patient, underwent
valve-sparing aortic root replacement and complicated triple ori-
fice mitral valve repair with 2 Alfieri stitches that perhaps, in hind-
sight, should not have been repaired.
Dr Stewart. The last comment is on your 2 most frequent com-
plications. One was the need in 8 patients for a right coronary ar-
tery interposition graft, which seems fairly high. The reason cited
was technical complications. However, that was 8 of 230. It seems
like a lot of right coronary injuries requiring a graft. I was wonder-
ing what you do to correct that.
Also, then, your patients withMarfan syndrome; 6 with a type B
dissection. I know that your group uses a pretty aggressive penin-
sula repair technique for the arch. I was unable to ferret out in your
Marfan group if they had received that technique and perhaps that
was predisposing them to a flow change in the distal arch and per-
haps that was not predisposing them to a dissection. Do you have
any comments on that?ery c January 2013
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DDr Kvitting. I will start with your last question. None of these
patients had undergone arch repair because they did not have bi-
cuspid valves. We know from others, for example, Professor Da-
vid’s data from Toronto, that downstream complications,
including the development of type B dissections, is known to occur
in patients with Marfan syndrome, which mandates assiduous sur-
veillance and careful b-blocker therapy with or without losartan.
We do not believe these dissections were related directly or indi-
rectly to our initial valve-preserving root replacement. Finally, re-
garding whether there was a high number of right coronary artery
injuries requiring an interposition graft, I cannot personally com-
ment on that. Sorry, sir.
Dr Smith. Dr Miller, did you want to answer that?
Dr D. Craig Miller (Stanford, Calif). Thank you, Craig. Being
responsible for most of them, indeed, I can comment. Most of these
patients had bicuspid valves and nondominant, small right coronary
arteries that fell apart during reimplantation with a Carrel patch. As
Tirone David andNickKouchoukos have shown,many early deaths
after aRoss procedure result from troublewith a small, nondominant
right coronary artery. Our solution for decades has been to do a very
short (2-3 cm) interposition graft using the large saphenous vein har-
vested from the thigh, termed a ‘‘Kay-Zubiate’’. JeromeKay andPa-
blo Zubiate in the late 1970s described how one can bail out of
trouble with this little vein graft. Interestingly, I just saw this very
old technique repopularized in a recent report with no reference
whatsoever to the original publication from decades ago. But, it
was due to technical problems, Allan; whether our rate was too
high, I do not know, but I do take responsibility for these problems.
Dr Christian Etz (Leipzig, Germany).On the same topic on the
bicuspids, you did not observe any difference in overall survival
among the 3 groups, obviously reflecting not only excellent patient
selection. We just presented our experience from Leipzig of a co-
hort of 476 patients of more than 1200 patients who underwent
root replacement, all with the samemechanical composite prosthe-
sis, at the Aortic Symposium in New York last week, and we found
similar results as you just presented, with an overall longevity
equivalent to an age- and gender-matched population after the first
postoperative year.
A subgroup analysis, however, in our bicuspid patients revealed
a significantly better long-term outcome; they were basically
cured, but those with tricuspid valves had significantly worse lon-
gevity after discharge, clearly inferior to that of their age- and gen-
der-matched normal population.
We also found, surprisingly, significantly worse longevity in
women, a finding that we had previously seen among patients re-
ceiving biological conduits in our Sinai series. So I was wondering
whether you had analyzed gender differences and could you com-
ment on your understanding as to what might protect bicuspid pa-
tients down the road?
Dr Kvitting. We have to go back and study whether gender
influenced the outcomes in our cohort. I saw your presentation
in New York. I am wondering a little bit whether perhaps your
data were biased because many of the tricuspid valves were prob-
ably associated with having some sort of connective tissue disorder
in a greater proportion than in patients with a bicuspid aortic valve
and that might be why having a bicuspid valve was protective, be-
cause they have less extensive aortic disease than the tricuspid
population. But that is just guessing from my side.The Journal of Thoracic and CaDr Etz. They were actually excluded. But perhaps it was be-
cause it is a mark of atherosclerosis. That was our understanding.
Also, our tricuspid valve population was significantly older than
yours, even older than those with bicuspid valves. So that also
might have shifted this a little bit.
Dr Oz Shapira (Jerusalem, Israel). Thank you for an excellent
presentation. My question is regarding the basic comparison
groups. Given that you had a large proportion of patients withMar-
fan syndrome in the tricuspid aortic valve group and a separate bi-
cuspid valve group, and given the large body of evidence
suggesting that a bicuspid aortic valve is associated with connec-
tive tissue disease of the aorta itself, would it have been more log-
ical to include the patients with Marfan syndrome and bicuspid
aortic valve in 1 group and compare them with the patients with
tricuspid aortic valves without Marfan syndrome? The long-term
adverse outcomes in the present study were mostly affected by
the presence of connective tissue disorder. Restructuring the study
groups might make a large difference in interpreting the results.
Thank you.
Dr Kvitting. That is a very good and valid point. We just dis-
cussed that point a few days ago, that perhaps we are giving the pa-
tients with tricuspid valves more than just 1 disease because they
are associated with a greater number of concomitant connective
tissue disorders. But it might be valuable to just try to do that
and group the valves together to determine whether valves with
or without associated aortic disease have a different outcome.
Dr Tirone E. David (Toronto, Ontario, Canada). This is more
a comment than a question. I think it is wonderful that you are doing
this operation and trying to determine its limitations. Whoever read
myveryfirst paper or heardmepresenting during thefirst decade, the
sentence I used was ‘‘normal’’ aortic cusps. During the first decade
of our experience, we never tried to do valve-sparing reimplantation
or remodeling in patients who had abnormal cusps. As experience
increased, we decided to treat patients with a bicuspid aortic valve
and prolapsing or defective cusps with large fenestrations.
Last week in New York City I presented Dr Feindel’s and my
experience with 296 reimplantations only. The longest follow-up
was 22 years. Unfortunately, only 21 patients were at risk at 15
years. Approximately one third had Marfan syndrome. Only 32
had bicuspid aortic valves. Only 11 patients developed moderate
or severe aortic insufficiency, one third of them in bicuspid aortic
valve group and none in the Marfan syndrome. Actually, on mul-
tivariate analysis, Marfan syndromewas the only independent pre-
dictor of AI on the beneficial side, that is, the hazard ratio was less
than 1. In other words, in our hands, Marfan syndrome was protec-
tive, not detrimental, to good outcomes.
Bicuspid aortic valve on univariate analysis was predictor of
failure but not on multivariate analysis. Again, our sample size
was too small.
Theanatomyof the bicuspidvalve ishighlyvariable.Type0 isper-
fect for valve sparing. If you have type 1 or 2 and the further away the
cusps are, the more difficult to perform a reimplantation into a cylin-
der or a Valsalva graft or the way you do the reimplantation.
I think we should be a bit more cautious with the reimplantation
technique in bicuspid aortic valve. Actually, in any reimplantation,
the cusps must be relatively normal for us to embark on this diffi-
cult operation.
Thank you.rdiovascular Surgery c Volume 145, Number 1 127
